Literature DB >> 8633572

Early detection of neoplasia of the esophagus and gastroesophageal junction.

R H Riddell1.   

Abstract

Recommendations for preventing adenocarcinoma: The standard definition of Barrett's epithelium should be the presence of intestinalized mucosa in the lower esophagus. Patients in this category should be considered for inclusion in a screening program for the detection of dysplasia or carcinoma. Those who are a poor operative risk should not be screened if the detection of an end-point such as high-grade dysplasia or intramucosal carcinoma will still not lead to resection. In some centers, however, alternative experimental methods of mucosal ablation may be available. The endpoint for screening is invasive or intramucosal carcinoma (or--in centers with a very low operative mortality--high-grade dysplasia). These should lead to consideration of surgery or, in specialized centers and as part of controlled studies, newer alternative modes of epithelial ablation. Intermediate markers, e.g., use of aneuploidy, gene markers, or their products, are at present experimental. Screening should be carried out annually or, possibly, biennially. This screening should utilize a standard protocol with an endoscope capable of obtaining large-particle biopsies. Four quadrant biopsies should be taken about every 2 cm, beginning 2 cm above the proximal limit of the gastric rugae, continuing until unequivocally in squamous mucosa, and following any tongues of glandular epithelium. Recommendations for prevention of squamous carcinoma: In high-risk populations, esophageal cytology, possibly supplemented by tests for blood in the stomach, appear most useful. Repeated screening may be necessary to detect early invasive or preinvasive (dysplastic) tumors. Although preliminary results from dietary intervention studies have yet to show a statistically significant decrease, if trends continue these will reach significance and may be the best overall method of cancer prevention. Measures to reduce smoking and drinking are to be encouraged, but their effectiveness is questionable. For patients who are positive on screening, endoscopy (possibly with Lugol's iodine) may provide the best indication of harboring underlying carcinoma or dysplasia. Endoscopic resection will play an increasing role in treatment. With the exception of tylosis, most other predisposing conditions are unlikely to be cost effective.

Entities:  

Mesh:

Year:  1996        PMID: 8633572

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  11 in total

1.  Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.

Authors:  Rebecca E Rudolph; Thomas L Vaughan; Alan R Kristal; Patricia L Blount; Douglas S Levine; Patricia C Galipeau; Laura J Prevo; Carissa A Sanchez; Peter S Rabinovitch; Brian J Reid
Journal:  J Natl Cancer Inst       Date:  2003-05-21       Impact factor: 13.506

Review 2.  Surveillance in Barrett's oesophagus: a personal view.

Authors:  K K Basu; J S de Caestecker
Journal:  Postgrad Med J       Date:  2002-05       Impact factor: 2.401

Review 3.  New developments in the endoscopic surveillance of Barrett's oesophagus.

Authors:  J J G H M Bergman; G N J Tytgat
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

4.  Neuromuscular function of the human lower oesophageal sphincter in reflux disease and Barrett's oesophagus.

Authors:  S D Smid; L A Blackshaw
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

5.  Ten years' experience of screening patients with Barrett's oesophagus in a university teaching hospital.

Authors:  C E Macdonald; A C Wicks; R J Playford
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

6.  Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium.

Authors:  K K Basu; B Pick; R Bale; K P West; J S de Caestecker
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

7.  Proliferative activity in Barrett's esophagus before and after antireflux surgery.

Authors:  L Q Chen; C Y Hu; L Gaboury; M Pera; P Ferraro; A C Duranceau
Journal:  Ann Surg       Date:  2001-08       Impact factor: 12.969

Review 8.  Role of surveillance in intestinal metaplasia of the esophagus and gastroesophageal junction.

Authors:  Guido N J Tytgat; Johanna W Van Sandick; J Jan B van Lanschot; Huug Obertop
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

9.  Zoning of mucosal phenotype, dysplasia, and telomerase activity measured by telomerase repeat assay protocol in Barrett's esophagus.

Authors:  James J Going; Aileen J Fletcher-Monaghan; Lisa Neilson; Bea A Wisman; Ate van der Zee; Robert C Stuart; W Nicol Keith
Journal:  Neoplasia       Date:  2004 Jan-Feb       Impact factor: 5.715

10.  The prevalence of human papilloma virus in esophageal squamous cell carcinoma.

Authors:  Sadat Noori; Ahmad Monabati; Abbasali Ghaderi
Journal:  Iran J Med Sci       Date:  2012-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.